MiCheck® Test

We have developed a prostate cancer blood test called MiCheck®. A series of clinical trials have shown it has superior specificity compared to prostate cancer blood tests that are available today.

MiCheck® fills the need for a test to assist physicians to decide whether or not a patient should proceed to a prostate biopsy following a high PSA reading.

  • More specific than a PSA test – so a urologist can tell if a biopsy is really needed.
  • Patients and their physicians will have confidence about what to do next.
  • Patients who should get treatment for prostate cancer will get it sooner, and men whose MiCheck® results are negative can be monitored regularly.

That means:

  • Fewer invasive tests – better for patients
  • Lower healthcare costs – better for healthcare budgets and insurers
  • More targeted testing– better for urologists and patients due to less patient anxiety, more efficient patient care, fewer infection risks

We are currently undertaking a US-based trial prior to its market launch.

%

PSA

%

MiCheck®

Miltuximab® for Therapeutic & Imaging Applications

Our patented antibodies target Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors.
We are examining multiple mechanisms of action including:

  • Radio immunotherapy
  • Antibody drug conjugates
  • Immune cell engagement and activation

We have commenced a first in-human trial using Miltuximab®, our anti-GPC-1 monoclonal antibody (ANZCTR registry).

In October 2016 Minomic announced the start of our first in-human trial using Miltuximab® conjugated to the radioactive isotope 67Gallium. We have now dosed a total of 6 patients with no adverse reactions whatsoever.

A Decade of Achievements

N

2007

Minomic formed to pursue opportunity in biomarkers based on MIL-38 monoclonal antibody

N

2009

Showed antibody binding to prostate cancer cells

N

2011

Received Venture Capital funding for commercialization

N

2014

Clinical validation studies for MiCheck® commenced

N

2016

Awarded Accelerating Commercialization grant to further product development

N

2016

Commenced First-in-Human trial of Miltuximab®

N

2017

Commenced MiCheck® Prospective Trial

2015 Eureka Prize

Excellence in Interdisciplinary Scientific Research

Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.

Find Out More Information

  • About our highly effective prostate cancer blood test >More
  • About our groundbreaking first in human trial of our novel cancer target >More
  • About how your company and Minomic could partner to deliver better prostate cancer diagnostics or therapeutics >More 

8 + 15 =

Address
Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia

Phone
International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here

Email
info@minomic.com

Finding Us
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

Headquarters of Minomic

Privacy Policy